We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

VRSK:NASDAQVerisk Analytics, Inc. Analysis

Data as of 2026-03-10 - not real-time

$202.83

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Verisk Analytics (VRSK) trades at $202.83, sitting above its 20‑day SMA but below the 50‑day and 200‑day averages, indicating a short‑term pullback within a longer‑term downtrend. The RSI hovers around 50, suggesting neutral momentum, while a bullish MACD histogram points to potential upside if buying pressure resumes. Volume has been tapering, and 30‑day volatility is elevated at nearly 50%, yet the stock’s beta remains low (Fundamentally, the company delivers strong margins (44% operating, 30% profit) and a solid cash conversion, but its balance sheet is strained with a net debt position and a debt‑to‑equity ratio exceeding 1,500%. The DCF fair‑value estimate of roughly $81 is far below the current price, flagging an overvaluation, though analysts project 4‑7% revenue growth and 6‑13% earnings growth through 2027, and a median price target of $230 suggests about 13% upside. A recent $1.5 B accelerated share repurchase and a $1 B senior‑note issuance indicate active capital management, while a sub‑1% dividend yield with a 28% payout ratio appears sustainable.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below 50‑day SMA and 200‑day SMA
  • Decreasing volume and high short‑term volatility
  • Bullish MACD suggesting possible rebound

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Analyst median target of $230 (+13% upside)
  • Projected earnings acceleration and modest revenue growth
  • Share repurchase program supporting price floor

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong operating margins and cash flow generation
  • Persistent high leverage and valuation gap to DCF
  • Sustainable dividend with modest payout ratio

Key Metrics & Analysis

Financial Health

Profit Margin29.56%
P/E Ratio31.3
ROE437.95%
ROA16.46%
Debt/Equity1581.80
P/B Ratio90.8
Op. Cash Flow$1.4B
Free Cash Flow$1.0B
Industry P/E29.6

Technical Analysis

TrendBearish
RSI50.5
Support$164.60
Resistance$216.65
MA 20$194.72
MA 50$206.60
MA 200$247.85
MACDBullish
VolumeDecreasing
Fear & Greed Index80.98

Valuation

Fair Value$80.97
Target Price$230.06
Upside/Downside13.42%
GradeOvervalued
TypeBlend
Dividend Yield0.95%

Risk Assessment

Beta0.28
Volatility49.84%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.